Ticker Details
XBiotech Inc. Common Stock XBiotech Inc is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases.
IPO Date:	April 13, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$71.04M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.27 | 2.90%
Avg Daily Range (30 D):	$0.04 | 1.53%
Avg Daily Range (90 D):	$0.04 | 1.82%

Institutional Daily Volume
Avg Daily Volume:	.12M
Avg Daily Volume (30 D):	.03M
Avg Daily Volume (90 D):	.04M

Trade Size
Avg Trade Size (Sh.):	120
Avg Trade Size (Sh.) (30 D):	189
Avg Trade Size (Sh.) (90 D):	167

Institutional Trades
Total Institutional Trades:	185
Avg Institutional Trade:	$1.7M
Avg Institutional Trade (30 D):	$1.87M
Avg Institutional Trade (90 D):	$1.87M
Avg Institutional Trade Volume:	.14M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.63M
Avg Closing Trade (30 D):	$4.37M
Avg Closing Trade (90 D):	$4.37M
Avg Closing Volume:	245.72K

News

Jan 14, 2025 @ 9:37 PM Wolf Haldenstein Adler Freeman & Herz LLP announce... Source: Wolf Haldenstein Adler Freeman & Herz Llp

Dec 24, 2024 @ 12:53 AM XBiotech suspend son programme de rhumatologie Source: N/A

Dec 24, 2024 @ 12:53 AM XBiotech setzt Rheumatologieprogramm aus Source: N/A

Aug 23, 2024 @ 3:51 PM Cancer Cachexia Market Forecasted to Reach $3.14 B... Source: Researchandmarkets.Com

Jun 19, 2024 @ 7:31 PM Ergebnisse aus randomisierter, doppelt verblindete... Source: XBiotech Inc.

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-1.49	$-.88	$-1.49
Diluted EPS	$-1.49		$-1.49
Revenue
Gross Profit
Net Income / Loss	$-45.54M	$-26.89M	$-45.54M
Operating Income / Loss	$-55.69M	$-29.76M	$-55.69M
Cost of Revenue
Net Cash Flow	$-47.13M	$-19.65M	$-47.13M
PE Ratio